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(HCC) in chronic liver diseases, which contributes both to increased hepatic vascular resistance and portal hypertension
and to decreased hepatocyte perfusion. On the other hand, recent evidence shows that angiogenesis modulates the forma-
tion of portal-systemic collaterals and the increased splanchnic blood ﬂow which are involved in the life threatening com-
plications of cirrhosis. Finally, angiogenesis plays a key role in the growth of tumours, suggesting that interference with
angiogenesis may prevent or delay the development of HCC. This review summarizes current knowledge on the molecular
mechanisms of liver angiogenesis and on the consequences of angiogenesis in chronic liver disease. On the other hand, it
presents the diﬀerent strategies that have been used in experimental models to counteract excessive angiogenesis and its
potential role in preventing transition to cirrhosis, development of portal hypertension and its consequences, and its appli-
cation in the treatment of hepatocellular carcinoma.
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HCC, hepatocellular carcinoma.representing the third cause of death in adults over 50
years old, as well as the indication for over 90% of the
5.000 liver transplants that are performed every year
within the EU. These features are increasing due to
the consequences of the hepatitis C epidemic in the
70’s. Thus, its socioeconomic impact is extraordinary.
The formation of new vessels (angiogenesis) and the
establishment of an abnormal angioarchitecture of the
liver is a process strictly related to the progressive ﬁbro-
genesis leading to cirrhosis and liver cancer. Investiga-
tion into these aspects is complex and certainly
requires a joint eﬀort of a multidisciplinary team of basic
investigators, pathologists, and hepatologists in the
areas of liver ﬁbrosis, hepatic circulation, and portal
hypertension and its complications.
Established evidence clearly indicates that chronic
liver diseases are characterized by intrahepatic vascular
remodelling with capillarization of sinusoids, ﬁbrogene-sociation for the Study of the Liver. Open access under CC BY-NC-ND license.
Table 1
Reversibility of liver ﬁbrosis according to the pattern.
Fibrosis pattern Early portal to
central septa
Neo
angiogenesis
Reversibility
Post-necrotic ++++ ++++ +
Biliary + ++ ++++
Centrolobular  ± ++++
Pericellular-
perisinusoidal
 ++ +++
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lead to increased hepatic resistance (and hence to
increased portal pressure) and decreased eﬀective hepa-
tocyte perfusion (and hence to liver failure). In addition,
new original data obtained by the authors of this review
suggest that vascular endothelial growth factor
(VEGF)/ platelet-derived growth factor (PDGF) driven
angiogenesis is of paramount importance in the forma-
tion of portal-systemic collaterals and of the hyperdy-
namic circulation which are responsible for the main
complications of cirrhosis often leading to death: gastro-
esophageal varices, massive upper gastrointestinal
bleeding, ascites, spontaneous bacterial peritonitis and
hepatic encephalopathy. Finally, angiogenesis is known
to play a critical role in the growth of tumours, which
makes it plausible to hypothesize that early interference
with angiogenesis signalling may prevent the transition
from hepatic dysplasia to HCC.
This article reviews the translational research eﬀort
that has been made recently on both the molecular
mechanisms and signal transduction cascade of liver
angiogenesis, and the consequences of angiogenesis in
chronic liver disease, emphasizing studies exploring dif-
ferent strategies to counteract excessive angiogenesis to
prevent progression of liver ﬁbrosis and transition to cir-
rhosis in chronic hepatitis, to prevent the development
of portal hypertension and its consequences, and ﬁnally
to prevent the formation and growth of hepatocellular
carcinoma often occurring in patients with cirrhosis.2. Angiogenesis and ﬁbrogenesis
Pathological angiogenesis, irrespective of the aetiol-
ogy, has been indeed extensively described in chronic
liver diseases (CLDs) characterized by an extensive
and prolonged necro-inﬂammatory and ﬁbrogenic pro-
cess, including chronic HBV, HCV and autoimmune
hepatitis [1,2], and primary biliary cirrhosis [3]. The for-
mation of new vessels, which is closely associated with
the pattern of ﬁbrosis development typical of the diﬀer-
ent CLDs [4], leads to the progressive formation of the
abnormal angio-architecture distinctive of cirrhosis, i.e.
the common end-point of ﬁbrogenic CLDs. Accord-
ingly, the association of ﬁbrogenesis and angiogenesis
should be regarded as crucial in the modern evaluation
of disease progression and in the search for therapeutic
targets. In addition, depending on the diﬀerent pattern
of ﬁbrogenic evolution (i.e. post-necrotic, biliary, cen-
trolobular, pericellular/perisinusoidal), the extent of
neo-angiogenesis may have profound consequences on
the rate of disease progression to cirrhosis and repre-
sents a key determinant aﬀecting reversibility of ﬁbrosis
(Table 1).
From a mechanistic point of view, angiogenesis in
ﬁbrogenic CLDs can be interpreted according to twomain pathways. First, the process of liver chronic
wound healing typical of ﬁbrogenic CLDs is character-
ized by an over-expression of several growth factors,
cytokines and metalloproteinases (MMPs) with an
inherent pro-angiogenic action [5]. In particular, plate-
let-derived growth factor (PDGF), transforming growth
factor-b1 (TGF-b1), ﬁbroblast growth factor (FGF) and
vascular endothelial growth factor (VEGF) have been
shown to exert a potent pro-ﬁbrogenic and pro-angio-
genic role. In addition, an increased gene expression of
integrins, b-catenin, ephrins, and other adhesion mole-
cules involved in extra-cellular matrix (ECM) remodel-
ling and angiogenesis has been clearly demonstrated in
CLDs [6,7]. Second, neo-angiogenesis is stimulated in
hepatic tissue by the progressive increase of tissue
hypoxia. This mechanism is strictly linked to the ana-
tomical modiﬁcations following the establishment of
periportal ﬁbrosis with an increased contribution of
the hepatic artery to the formation of sinusoidal blood
[8]. Accordingly, sinusoidal blood ﬂow becomes increas-
ingly arterialized with hepatocytes adjusting to an
abnormally high oxygen concentration. Subsequently,
the progressive capillarization of sinusoids leads to an
impairment of oxygen diﬀusion from the sinusoids to
hepatocytes with the consequent up-regulation of pro-
angiogenic pathways [9–11].
Although neo-angiogenesis is a common feature of
most chronic inﬂammatory and ﬁbrogenic disorders
[12,13], hepatic angiogenesis may substantially diﬀer
from homologous processes in other organs or tissue
on the basis of: (a) the rather unique phenotypic proﬁle
and functional role of activated hepatic stellate cells
(HSC) and of other liver myoﬁbroblasts (MFs) [14–20]
(b) the presence of two diﬀerent microvascular struc-
tures described (i.e., sinusoids lined by fenestrated endo-
thelium versus large vessels lined by a continuous one);
(c) the existence of ANGPTL3, a liver speciﬁc angio-
genic factor [21]. Evidence obtained from morphological
studies suggests that angiogenesis occurring in hepatic
tissue undergoing chronic wound healing is character-
ized by branching of neo-vessels from the existing vascu-
lature. The large majority of these neo-vessels originate
from the ﬁne portal vein branches and tend to establish
a connection between the portal system and the hepatic
veins [8,22]. The role of bone marrow-derived endothe-
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has been suggested by studies employing animal models
of hepatic ﬁbrogenesis [23,24] and needs to be substanti-
ated in human CLDs.
A key area in the study of the cellular and molec-
ular relationships existing between ﬁbrogenesis and
angiogenesis concerns the pro-angiogenic role of acti-
vated HSC and other ECM-producing cells such as
portal ﬁbroblasts and myoﬁbroblasts. Hypoxic condi-
tions, through the involvement of the transcription
factor HIF-1a, are able to up-regulate expression of
VEGF [2,17,25–27] and angiopoietin I [17,26] in rat
or human HSC. Moreover, exposure to hypoxia
results in up-regulation of VEGF receptors type I
(Flt-1) and type II (Flk-1) as well as of Tie-2 (i.e.,
the receptor for angiopoietin I) in the same cell type
[11,17,25]. Hypoxia-dependent up-regulation and
release of VEGF by human HSC/MFs can stimulate,
in a paracrine and/or autocrine manner, non-oriented
migration and chemotaxis of human HSC/MFs [17].
This feature depends mainly on the interaction
between VEGF and Flk-1 and may explain the signif-
icant ‘‘in vivo” anti-ﬁbrotic eﬀect reported in an exper-
imental model in which animals were treated with
neutralizing anti-Flk-1 antibodies [28]. Recent
‘‘in vivo” data obtained in human and rat ﬁbrotic/cir-
rhotic livers, indicate that a-SMA-positive cells (i.e.,
myoﬁbroblast-like phenotype) expressing VEGF,
Ang-1 or the related receptors Flk-1 and Tie-2, are
consistently localized at the leading edge of tiny and
incomplete developing septa, but not in larger bridg-
ing septa [17]. This distribution may reﬂect two diﬀer-
ent phases of angiogenic process during chronic
wound healing: an early phase, occurring in develop-
ing septa, in which ﬁbrogenesis and angiogenesis
may be driven/modulated by ECM-producing cells,
and a later phase occurring in larger and more mature
ﬁbrotic septa where the chronic wound healing is less
active and ﬁbrogenic transformation more established.
In this latter setting pro-angiogenic factors are
expressed only by endothelial cells, a scenario that is
likely to favour the stabilization of the newly formed
vessels. In this context, it is relevant that the promo-
tion of a pro-angiogenic phenotype in activated HSC
is stimulated also by non-hypoxic conditions and par-
ticularly by the exposure to the pro-ﬁbrogenic adipo-
kine leptin [26].
An elegant and convincing demonstration of the
interplay between inﬂammatory response, angiogenesis,
and ﬁbrogenesis has been recently provided by an exper-
imental study in which all these features have been sig-
niﬁcantly reduced by the treatment with the
multitargeted receptor tyrosine kinase inhibitor suniti-
nib [29]. This study is of relevance because it provides
evidence for a possible dual and converging pharmaco-
logical action (i.e. anti-ﬁbrogenic and anti-angiogenic)able to interfere directly with liver myoﬁbroblasts, pre-
sumably by negatively aﬀecting PDGF-dependent
signalling.3. Role of angiogenesis in portal hypertension
Portal hypertension is a major complication of cir-
rhosis of the liver, which represents a leading cause of
death and liver transplantation [30–32]. A salient feature
of portal hypertension is the formation of an extensive
network of portosystemic collateral vessels, which
include the oesophageal and gastric varices, responsible
for variceal bleeding, associated with a high mortality
rate [30–32]. In addition, collateral vessels result in
shunting of portal blood into the systemic circulation,
causing high systemic concentrations of several sub-
stances normally metabolized by the liver, such as drugs,
toxins, hormones, and bacteria. These in turn contribute
to severe complications of cirrhosis, including portosys-
temic encephalopathy and sepsis [30–32]. Therefore, suc-
cessful design of medical treatment for portal
hypertension requires a better understanding of the
mechanisms underlying the formation of portosystemic
collateral vessels, an issue that has remained largely
unexplored. Traditionally, formation of collaterals was
considered to be a mechanical consequence of the
increased portal pressure that will result in the opening
of these vascular channels. Accordingly, therapeutic
strategies are mainly aimed at decreasing portal pressure
[30–32]. However, as discussed in this article, recent
studies have examined another approach, based on the
potential involvement of angiogenesis in the develop-
ment of these collateral vessels.
Another characteristic feature of the portal hyperten-
sive syndrome is the development of a hyperdynamic cir-
culatory state, with an increase in blood ﬂow in
splanchnic organs draining into the portal vein and a
subsequent increase in portal venous inﬂow [30–32].
Such an increased portal venous inﬂow represents a sig-
niﬁcant factor maintaining and worsening portal hyper-
tension [30–32]. The mechanisms underlying this
splanchnic hyperemia are not fully understood, but
involve overproduction of endogenous vasodilators
and decreased vascular reactivity to vasoconstrictors
[30–32]. An intriguing possibility is that an increased
formation of splanchnic blood vessels through active
angiogenesis could also be involved in the maintenance
of a hyperdynamic splanchnic circulation in portal
hypertension.
In the last few years, these possibilities have been
addressed by studying the eﬀects of diﬀerent anti-angio-
genic strategies aimed at inhibiting the signalling path-
ways of vascular endothelial growth factor (VEGF),
platelet-derived growth factor (PDGF), and placental
growth factor (PLGF), which are essential mediators
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nance of hyperdynamic splanchnic circulation and por-
tosystemic collateralization in experimental models of
portal hypertension.
3.1. Increased angiogenesis in portal hypertension
Evidence supporting a role for angiogenesis in the
pathogenesis of portal hypertension includes recent
investigations demonstrating that VEGF, a potent
angiogenic factor [35], is overexpressed in splanchnic
organs from portal hypertensive animals (Fig. 1)
[36,37]. The expression of VEGF receptor-2 (VEGFR-
2) and the endothelial cell marker CD31 [38] is also
increased in the splanchnic territory in experimental
models of portal hypertension [36,37]. These and other
studies provided evidence of increased VEGF-driven
splanchnic angiogenesis in portal hypertensive animals
and in cirrhotic patients [39–42].
The precise mechanism triggering VEGF-dependent
angiogenesis in portal hypertension remains speculative,
but it is likely to be multifactorial. Indeed, several fac-
tors relevant to the pathogenesis of portal hypertension,
such as tissue hypoxia, cytokines, and mechanical stress,
have been shown to promote VEGF expression in vari-
ous cell types and tissues [30–32,35].
3.2. VEGF signalling blockade in portal hypertension
Recent studies have determined the eﬀects of several
angiogenesis inhibitors, with diﬀerent modes of action,
in experimental models of portal hypertension. These
studies demonstrated that treatment with an anti-VEG-
FR-2 monoclonal antibody (DC101) [43] from the
induction of portal hypertension markedly decreased
the formation of portosystemic collateral vessels and
reduced splanchnic vascularization in portal hyperten-
sive mice [36]. Similar results were obtained using
SU5416, a speciﬁc inhibitor of the tyrosine kinase
domain of VEGFR-2 [37,44] as an anti-angiogenic strat-
egy, which caused a signiﬁcant 52% decrease in the
extent of portosystemic collateral formation in rats with
partial portal vein ligation (PPVL) [37]. In addition,
SU5416 also markedly reduced the splanchnic hyperdy-
namic circulation in these animals, indicating that
increased splanchnic arteriolar bed size mediated by a
VEGF-dependent angiogenic process signiﬁcantly con-
tributes to the increased portal blood inﬂow. Portal
pressure however was not modiﬁed, most likely because
of the concomitant inhibition in the formation of porto-
systemic collateral vessels [37]. These ﬁndings were fur-
ther conﬁrmed using rapamycin, which inhibits VEGF
production and reduces portosystemic collateral vessel
formation by 67% in portal hypertensive rats, in parallel
with a signiﬁcant attenuation of the hyperdynamic
splanchnic circulation [45].Taken together, these data indicate that the develop-
ment of hyperdynamic splanchnic circulation and
splanchnic neovasculature as well as the formation of
portosystemic collateral vessels in portal hypertensive
animals are in part VEGF-dependent angiogenic pro-
cesses that can be signiﬁcantly prevented by inhibitors
of the VEGF/VEGF receptor-2 signalling pathway,
when its administration was started at the time of portal
hypertension initiation [36,37,45].
3.3. Combined VEGF and PDGF signalling blockade
The studies described so far highlight the importance
of angiogenesis in the pathogenesis of portal hyperten-
sion and suggest that anti-angiogenic treatment might
be a promising therapeutic strategy to prevent the pro-
gression of the portal hypertensive syndrome
[36,37,45]. In clinical practice, however, portal hyperten-
sion does not represent a signiﬁcant problem until it is
quite advanced and associated with clinical manifesta-
tions. Thus, for anti-angiogenic treatment strategies to
become of great clinical relevance these should be able
to revert the circulatory abnormalities associated with
portal hypertension once these are fully developed [45].
In this regard, it should be noted that in the process
of neovascularization, VEGF plays a predominant role
in the initial stages of formation of new blood vessels,
activating the proliferation of endothelial cells and the
subsequent formation of an endothelial tubule, while
maturation of the newly formed vessels is mainly modu-
lated by the proangiogenic growth factor platelet-
derived growth factor (PDGF), which regulates the
investiture of the endothelial tubule with mural cell
and pericyte populations, thereby stabilizing the vascu-
lar architecture of the nascent vessel [33,46]. Based on
these considerations, it was hypothesized that the simul-
taneous targeting of the VEGF and PDGF signalling
pathways, that is the simultaneous targeting of endothe-
lial cells and pericytes, could provide a greater vascular
destabilization and a better vascular regression than tar-
geting either alone.
It was ﬁrst demonstrated that development of portal
hypertension in PPVL rats was associated with a pro-
gressive overexpression of PDGF, which reached its
peak later in the course of portal hypertension than
VEGF overexpression [45]. In accordance with the
working hypothesis, the continued administration of
the VEGF signalling inhibitor rapamycin plus the
PDGF signalling inhibitor Gleevec markedly
decreased the splanchnic neovascularization and the
pericyte coverage of neovessels in portal hypertensive
rats (Fig. 2) [45]. This combined treatment also resulted
in a virtually complete reversal of the increased portal
pressure (40% reduction) and the increased portal
venous blood inﬂow of these animals (Fig. 3). This is
important since clinical studies have shown a dramatic
Fig. 1. Overexpression of VEGF, VEGF receptor-2, and CD31 in portal hypertensive mice. (Left) Protein expressions in splanchnic organs from partial
portal vein-ligated (PPVL) mice and sham-operated (SO) control animals, seven days after the initial surgery. (Right) Protein expressions at days 1, 5,
and 7 after the induction of portal hypertension in mice. Representative western blots are shown at the top and densitometric quantiﬁcation normalized to
a-tubulin is shown at the bottom of each panel. *P < 0.05 vs. SO mice (left) or vs. day 1 (right).
608 M. Ferna´ndez et al. / Journal of Hepatology 50 (2009) 604–620reduction of the risk of portal hypertensive complica-
tions and improved survival in patients achieving a
decrease in portal pressure of at least 20% under drugtherapy. Notably, the magnitude of the eﬀects of the
combination treatment was superior than the addition
of the eﬀects of either drug alone, suggesting a synergis-
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signalling pathways in mediating the maintenance of the
vascular and hemodynamic abnormalities observed in
portal hypertensive rats [45]. These ﬁndings further sug-
gest that in the absence of proliferating perivascular cells
(ie, after PDGF signalling inhibition), the endothelium
is more vulnerable to anti-angiogenic therapies targeting
endothelial cells, such as VEGF signalling blockade [47].
Overall, these ﬁndings demonstrate that angiogenesis
is a pathological hallmark of portal hypertension, and
have made the control of new blood vessel formation
a promising therapeutic target to prevent the progres-
sion and to promote the regression of portal hyperten-
sion-related complications in clinical scenarios.
3.4. Role of PLGF-derived angiogenesis in portal
hypertension
Placental growth factor (PLGF) was originally dis-
covered in human placenta in 1991 and is a member ofFig. 2. Eﬀects of rapamycin (RAPA), Gleevec or RAPA + Gleevec on angioge
Expression of CD31, VEGF, VEGFR-2, PDGF, PDGFR-beta, and a-smooth
RAPA, Gleevec, RAPA + Gleevec or vehicle. Representative blots are shown at
at the right. (a) P < 0.05 vs. PPVL-vehicle. (b) P < 0.05 vs. PPVL-RAPA. (B
H&E from PPVL and SO rats treated with RAPA or vehicle. Original ma
mesentery from PPVL and SO rats treated with RAPA or vehicle. (a) P < 0.0the VEGF family. Alternative splicing of the human
PLGF gene generates three isoforms (PLGF-1, PLGF-
2, and PLGF-3), while in mice only PLGF-2 is present
[48]. The 3-dimensional structures of VEGF and PLGF
are similar; however they have only 42% identical
amino-acids [48,49].
PLGF is not highly expressed in normal tissue and
during embryogenesis, as PLGF-deﬁcient mice are via-
ble and fertile and do not display major abnormalities
[49–53]. In the healthy state, PLGF plays a role during
pregnancy and during the ovarian cycle, without aﬀect-
ing quiescent vessels. However, loss of PLGF impairs
angiogenesis in the wounded skin, ischemic retina, limb,
heart and in cancer, whereas administration of recombi-
nant PLGF (rPLGF) promotes collateral vessel growth
in models of limb and myocardial ischemia [50,54].
Placental growth factor binds only to VEGFR-1 and
neuropilin-1 and enhances the eﬀects of VEGF and thus
angiogenesis only under pathological conditions [54–56].
VEGFR1 is minimally expressed in adult quiescent ves-nesis mediators when portal hypertension was completely established. (A)
muscle actin (a-SMA) in the intestine of PPVL rats after treatment with
the left and quantiﬁcation of expression normalized to a-tubulin is shown
) Representative histological images of mesentery sections stained with
gniﬁcation 40. (C) Quantitative analysis of neovascularization in the
5 vs. PPVL-vehicle.
Fig. 3. Eﬀects of RAPA, Gleevec or RAPA + Gleevec on splanchnic hemodynamics when portal hypertension was completely established. (a) P < 0.05 vs.
SO-vehicle; (b) P < 0.05 vs. SO-RAPA; (c) P < 0.05 vs. SO-Gleevec; (d) P < 0.05 vs. PPVL-vehicle.
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lated during pathological conditions, stimulating the
PLGF-dependent angiogenic signals [55]. This makes
PLGF attractive as a therapeutic target [49,55]. The syn-
ergistic eﬀects between PLGF and VEGF are shown in
Fig. 4.
3.5. Eﬀects of the PLGF/VEGFR1 signalling pathway
PLGF reconstitutes haematopoiesis by recruiting
VEGFR1 positive stem cells from the bone marrow,
stimulates the survival of endothelial cells and mono-
cytes [56–58], and plays an important role in inﬂamma-
tion by recruiting endothelial cells, monocytes,
progenitor cells and functional natural killer cells and
by stimulating migration of inﬂammatory cells and che-
motaxis. Leukocytes and inﬂammation can cause the
release of multiple angiogenic factors such as VEGF,
platelet-derived growth factor (PDGF), PLGF and basic
ﬁbroblast growth factor [59].
PLGF is also a major player in arteriogenesis (and
mature vessel formation) via recruitment of bone mar-
row cells, smooth muscle cells, pericytes, endothelial
cells and monocytes [60]. PLGF enhances collateral
growth by stimulating endothelial and smooth muscle
cell growth. Other angiogenic factors such as VEGF,
PDGF, and angiopoetin 1 enhance the formation of col-
laterals [51,59–63].
3.6. PLGF in portal hypertension
Geerts et al. have recently demonstrated that neo-
angiogenesis in the mesentery of portal hypertensive
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PLGF protein levels, and CD31 (marker for endothelial
cells and thus angiogenesis) [64,65].
Recent studies usingPLGFknockoutmice (PLGF/)
have shown that PLGF(/) portal hypertensivemice do
not develop mesenteric neo-angiogenesis. CD31 protein
expression in portal hypertensive PLGF(/) mice was
signiﬁcantly lower than in portal hypertensive wild-type
mice, and similar to those of sham operated mice
[64,65]. This was also conﬁrmed by immunohistochemis-
try. Portal hypertensive PLGF(/) mice showed a ten-
dency towards a lower portal pressure and a signiﬁcant
decrease (but not normalization) in spleen weight
[64,65]. These ﬁndings conﬁrm that portal hypertension
induces neo-angiogenesis and that this plays a role in
the maintenance of the splanchnic hyperdynamic state.
The lack of reduction in portal pressure in PLGF(/)
mice is in accordance with previous observations inhibit-
ing VEGF [36,37,45]. Further studies with anti-PLGF
antibodies in the prevention and treatment of portal
hypertension are underway. As the role of PLGF is espe-
cially restricted to pathological conditions it is a good tar-
get for therapywith potentially less severe side eﬀects than
the blockade of VEGF/PDGF.4. Angiogenesis in liver regeneration
Much of our knowledge about vascular biology of
the liver has come from studying angiogenesis during
regeneration after partial hepatectomy. The diﬀerent
phases of physiological angiogenesis and sinusoidal
remodelling during liver regeneration have been ana-
lyzed extensively. Dysregulation of the same pathways
and processes in chronic liver disease leads to endothe-
lial dysfunction, pathological angiogenesis, with forma-
tion of collaterals and eventually to portal hypertension.
This section summarizes the timely, limited, highly
orchestrated cellular and molecular interactions related
to physiological angiogenesis during liver regeneration.
4.1. Role of liver sinusoidal endothelial cells in liver
regeneration
The liver receives 25% of the total cardiac output,
which arrives via the hepatic artery (1/3 of hepatic blood
ﬂow) and the portal vein (2/3 of hepatic blood ﬂow).
Blood ﬂows through liver sinusoids, a unique microvas-
culature which consists of plates of liver sinusoidal
endothelial cells (LSECs) between plates of hepatocytes,
before coming in contact with the liver parenchyma.
LSECs account for 20% of total liver cells (an estimated
1  108 cells) whereas hepatocytes represent the major-
ity of liver cells (estimated 60% or 3  108 cells). LSECs
have a unique phenotype in comparison to other organs
characterized by a discontinuous, fenestrated endothe-lium, which lacks an organized basement membrane.
Cellular cross-talk between LSECs and hepatocytes
plays an important role in sinusoidal homeostasis and
physiologic angiogenesis during liver regeneration and
hepatic organogenesis.
Following partial hepatectomy (up to 70% removal),
the liver will completely regenerate and reach its original
functional mass with normal microscopic architecture,
which is a unique capacity compared to all other organs
with none or only limited regeneration. Experimental
partial hepatectomy (PHx) involves the removal of
two-thirds of the liver [66]. Within 8–10 days, the liver
remnant enlarges, until the previous functional liver
mass is restored. LSECs and hepatocytes in the normal
liver are quiescent, with only 0.01–0.001% undergoing
mitosis at any given time. PHx activates numerous tran-
scription factors, induces the expression of more than 70
genes, and promotes cell cycle entry with synchronous
proliferation of almost all hepatocytes by 24–36 h
post-PHx. The initial wave of hepatocyte proliferation
is followed by a second wave of replication of non-
parenchymal liver cells, including LSECs and HSC,
which start to proliferate 48–72 h after resection peaking
at day 4–5 [67].
Hemodynamically seen, PHx leads to an increased
sinusoidal blood ﬂow since the portal inﬂux to the liver
remnant remains unchanged [68]. Hemodynamic
changes and shear stress might induce hepatocyte prolif-
eration through activation of urokinase plasminogen
activator, matrix remodelling, and subsequent release
of preformed hepatocyte growth factor (HGF) [69].
The initial proliferation of hepatocytes leads to the for-
mation of avascular clusters of hepatocytes, where the
central cells reside outside the oxygen diﬀusion distance
of 200 lm of a capillary [67,70,71]. This is accompanied
by ultrastructural changes of the sinusoids, with external
compression of the sinusoids by proliferating hepato-
cytes, decrease of sinusoidal fenestrations and endothe-
lial porosity 72 h post-PHx [71]. In a next stage,
hypoxia and hepatocyte signalling induce LSEC activa-
tion, proliferation, and migration of neighbouring
LSECs into the avascular clusters [72,73]. This leads to
separation of hepatocytes with subsequent recanaliza-
tion and formation of patent sinusoids. Around day 6
after PHx (when the regenerating liver is approaching
its preoperative functional mass), a wave of apoptosis
in LSEC can be detected with a maximum at day 8
[70,74,75]. This is in contrast to hepatocytes which do
not show increased apoptotic rates during the regenera-
tive process [70]. Eight to 10 days following PHx, liver
mass is fully reconstituted, and the sinusoidal architec-
ture restored to normal.
Circulating endothelial progenitor cells (character-
ized by stem cell markers such as CD117 or CD133)
have also been shown to play a role in angiogenesis dur-
ing liver regeneration. Circulating endothelial cells are
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growth factors and chemokines produced in the regener-
ating liver and participate in this process by homing to
sites of neovascularization in the liver and by commit-
ting to LSECs [76,77]. Treatment with exogenous VEGF
increased mobilization of circulating endothelial progen-
itor cells and accelerated liver regeneration in mice after
PHx [76].
4.2. Sinusoidal remodelling in the regenerating liver
Recent evidence suggests that an alternative mode of
angiogenesis, called intussusceptive angiogenesis contrib-
utes to the angiogenic process in addition to the classical
form of sprouting angiogenesis described above. Sprout-
ing (angiogenesis from a pre-existing vascular bed) is
dependent on endothelial cell proliferation with subse-
quent lumen formation in the sprout. In contrast to
sprouting, angiogenesis by intussusception consists of
microvascular remodelling by transcapillary pillar for-
mation and relies much less on endothelial cell prolifer-
ation [78,79]. Growth of these endothelial pillars leads to
sinusoidal multiplication by successive fusion and parti-
tioning of the existing vascular lumen. Intussusceptive
angiogenesis has been found to occur as early as 12 h
after PHx in mice [80]. The split sinusoids increase in
girth and undergo augmentation by day 3 to 4, concom-
itant with endothelial cell proliferation [80].
The role of HSC in liver regeneration and sinusoidal
remodelling is less well studied. HSC are closely associ-
ated with LSEC and function as liver-speciﬁc pericytes
(vascular mural cells of the hepatic sinusoids) [16,81].
They regulate vessel stabilization, maturation and sinu-
soidal remodelling by direct contact and paracrine inter-
action with LSECs such as secretion of VEGF [16].
Mediated by platelet-derived growth factor (PDGF)
produced by hepatocytes and LSECs, resting HSC start
to proliferate (peaking at 48–72 h) and become activated
within the ﬁrst 72 h after PHx [69,82–84]. In addition,
HSC are thought to control remodelling of the extracel-
lular matrix in the space of Disse during regeneration
(i.e. deposition of collagen IV, ﬁbronectin and laminin)
which will inﬂuence function of LSECs [69,71,82]. Sim-
ilar to circulating endothelial progenitor cells, bone mar-
row-derived cells have also been shown to commit to
HSC during liver regeneration [85].
4.3. Hypoxia and vascular factors regulate angiogenesis
during liver regeneration
VEGF is the most important growth and survival fac-
tor for endothelium. VEGF promotes proliferation of
endothelial cells, acts as an anti-apoptotic factor and
regulates vascular permeability by inducing fenestration
in LSECs [86,87]. Furthermore, VEGF induces the
expression of proteases like collagenase [88], matrixmetalloproteinases [89], urokinase- and tissue-type plas-
minogen activators [90], which enable endothelial cells
to breakdown the surrounding extracellular matrix in
order to migrate and form new blood vessels. VEGF is
constitutively expressed in hepatocytes at low levels
[91]. VEGF production by hepatocytes and HSC rapidly
increases during liver regeneration. of VEGF is induced
by cytokines (i.e. IL-6) and hypoxia in the centre of the
regenerative and avascular hepatocyte clusters [67].
Hypoxia activates the transcription factor hypoxia-
inducible factor (HIF)-1, which in turn induces the
expression of downstream target genes including cMet,
EPO (erythropoietin), VEGF and VEGFR-1 (VEGF
receptor 1) [92–94]. Hepatocyte production of VEGF
peaks 48–72 h after PHx and is detected mainly in peri-
portal hepatocytes [72,91]. Administration of VEGF in
hepatectomized rodents increases LSEC and hepatocyte
proliferation [91,95], accelerates gain in liver mass [96]
and improves functional hepatic recovery [93]. Trans-
duction of VEGF before hepatic resection also hastens
functional hepatic recovery in mice with fatty liver,
which is known for its impaired regenerative capacity
[93]. Neutralizing antibodies against VEGF inhibit
hepatocyte and endothelial cell proliferation after PHx
[91].
VEGF production is accompanied by an increase in
the expression of the VEGFR-1 on hepatocytes and of
VEGFR-1 and VEGFR-2 on LSECs [67,73,93,97]. Acti-
vation of VEGFR-2 stimulates LSEC proliferation. On
the other hand, binding of VEGF to VEGFR-1 on
LSEC induces secretion of growth and survival factors
such as HGF and interleukin-6 (IL-6), which in turn
stimulate hepatocyte proliferation and reduce liver dam-
age in mice exposed to CCl4 [96]. This suggests an angi-
ogenesis-independent endothelial protection of
hepatocytes through VEGFR-1.
In addition to VEGF and HGF, other angiogenic
growth factors and their receptors are upregulated
during liver regeneration, including PDGF, FGF
and angiopoietins. Angiopoietins Ang1 and Ang2 reg-
ulate vessel stability by activating (Ang1) or antago-
nizing (Ang2) signalling via the receptor tyrosine
kinase Tie2 [16]. Ang1 stabilizes vessels by promoting
pericyte recruitment. Tie2 which is expressed by
LSECs and its ligands Ang1 and Ang2 increases dur-
ing liver regeneration [67,73,75,98]. The orphan recep-
tor Tie1 was found to be expressed on LSECs
surrounding avascular hepatocyte clusters [67]. Neu-
ropilin-1 and Neuropilin-2 are recently discovered
VEGF co-receptors unrelated to VEGFR-1 and -2,
which have no intrinsic signalling but enhance bind-
ing of VEGF to VEGFR-2 [99,100]. Neuropilin-1
has been shown to be upregulated regenerating livers
[98,101].
Thrombocytes play an important role in liver regen-
eration [102]. Thrombocytes contain high concentra-
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PDGF) as well as inhibitors (i.e. endostatin, thrombo-
spondin 1) packaged in distinct populations of a-gran-
ules which can be released selectively [74,103].
Although unexplored, one can speculate that as throm-
bocytes adhere to activated endothelium their action can
enhance or inhibit local angiogenesis and thereby inﬂu-
ence liver regeneration.
In summary, intense research using partial hepatec-
tomy in animal models leads to identiﬁcation of mecha-
nisms and pathways which regulate angiogenesis in the
liver. Emerging antiangiogenic drugs are under investi-
gation to counterbalance dysregulated angiogenic path-
ways in chronic liver disease and HCC and are discussed
in the other sections.5. Angiogenesis and liver cancer
The growing incidence of hepatocellular carcinoma
(HCC) on a worldwide scale [104] and the current capac-
ity to diagnose and treat this cancer at an early stage has
raised interest in this neoplasm [105,106]. It is well
known that in most patients, this malignancy emerges
in a liver with long-standing cell damage that has
resulted in extensive ﬁbrosis or cirrhosis [106]. In fact,
HCC development is now a leading cause of death in cir-
rhotic patients. This has prompted major research activ-
ity into all aspects related to the pathogenesis and
clinical translation of laboratory data into clinical
practice.
There are several in-depth reviews that expand into
the genomic abnormalities that might be found in
experimental liver tumours as well as in cell lines
and human tumour tissue banks [107–110]. An enor-
mous amount of data describing chromosome abnor-
malities and gene expression has been published in
recent years and gene expression has also been tenta-
tively correlated with prognosis both with and without
treatment application. Furthermore, analysis of
tumours obtained at diﬀerent evolutionary stages have
allowed to propose gene events that herald the trans-
formation of premalignant clones into overt HCC
[111] and at the same time, the recognition of diﬀerent
gene expression patterns have triggered the proposal
of a molecular classiﬁcation of HCC [112–114]. Fur-
thermore, the dissection of the derangement of several
signal transduction pathways that govern cell prolifer-
ation, invasion and survival [115] has fuelled the
development of new agents aimed at targeting the spe-
ciﬁc event that is responsible for cancer evolution
[116]. Blockade of the eﬀective signalling by growth
factors has been generated in the benches and some
of them have reached human testing. The same applies
for the pathways that are abrogated and permit malig-
nant cell survival, and also for the diﬀerent moleculesthat are involved in the active neoangiogenic process
that characterize all cancer types [117].
It is important to note that HCC is a highly vascular-
ised tumour. Hence, proﬁling and targeting of the steps
leading from a premalignant poorly vascularised nodule
to the transition into an overt malignant phenotype with
enhanced arterial blood supply has become a landmark
event both for diagnosis, current treatment and novel
therapeutic approaches [117,118].
5.1. Clinical relevance of the vascularization proﬁle in
HCC
The cell origin of HCC is not well-established. It may
derive from hepatic stem cells or from the transforma-
tion from dysplastic hepatocytes into malignant cells.
This last evolution has been quite well characterized in
recent years [119] when imaging techniques have permit-
ted the monitoring of the evolution from a small (<1 cm)
hypoechoic nodule within a cirrhotic liver into typical
HCC [120]. Small hypoechoic nodules have been given
diﬀerent names that include adenomatous hyperplasia,
dysplastic nodule, macroregenerative nodule with dys-
plastic changes, but recently have been divided into
regenerative nodules and low or high-grade dysplastic
nodules [121,122]. The risk of malignant transformation
of the ﬁrst type is nil, it is minimal in the low-grade cat-
egory and is really high in the nodules classiﬁed as high-
grade dysplastic nodules [122]. All of them have a blood
supply dependent from the portal vein, the hepatic
artery supply being absent [123]. Because of this charac-
teristic, the nodules are recognised as hypoechoic at
plain ultrasonography and characteristically lack con-
trast uptake in the arterial phase if explored by contrast
enhanced-US, dynamic CT or MRI [124]. In some cases
the progressive transition into early HCC is associated
with fat accumulation that turns the nodule into hyper-
echoic. If the nodule is ﬁrst detected at that stage, it
might be wrongly suspected to correspond to a small
angioma, while it indeed corresponds to a transformed
clone that it is likely to have experienced oxidative stress
due to impaired blood supply. If stress is excessive some
apoptotic death will take place, but ultimately, the
malignant proﬁle is established and overt cancer is in
place. At this point, the vessel pattern has sharply chan-
ged and arterial supply is predominant. This feature is
the basis for the imaging diagnosis of HCC within a cir-
rhotic liver [118,124]. Conﬁdent diagnosis is easy in
large HCC as the vascular bed is fully established. How-
ever, at an early stage the arterial net is not extensive
enough and only one-third of the nodules ultimately
corresponding to an HCC can be conﬁdently diagnosed
by imaging characterization, the rest requiring a diag-
nostic biopsy.
Recent studies have tried to correlate gene expression
in tumour tissue with imaging characterization [125].
Fig. 5. BCLC-9 cell line derived from a human HCC. It has been shown
to produce VEGF that is further enhanced under hypoxic conditions
[131].
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expected that a more sensitive assessment will be
obtained through metabolic/molecular characterization
by MRI, rather than with the mere evaluation of con-
trast behaviour. In that sense, the clinical need and
urgent research challenge is not to classify already
advanced cancer, but to characterize small nodules. It
is crucial to conﬁdently establish if they have not yet
reached the oncogenic capacity or if they are already
entering the neoangiogenic stage that precedes malig-
nant evolution.
Detailed pathology studies carried out by the team of
M Kojiro in Kurume, Japan have further divided small
HCC into two diﬀerent types: distinctly nodular vs.
vaguely nodular [123]. The latter is assumed to corre-
spond to the carcinoma in situ entity and lacks any inva-
sive feature. By contrast, the distinctly nodular HCC
type is clearly more evolved. A surrounding ﬁbrotic cap-
sule is more frequently observed and it exhibits a higher
rate of microscopic vascular invasion. Interestingly, the
transition from carcinoma in situ to established cancer is
associated with the appearance of the prominent arterial
blood supply that might be recognised by dynamic
imaging techniques. Immunohistochemical staining is
able to capture this neovessel formation and thus, stain-
ing for endothelial cells to display isolated arteries
within a nodule is used as a diagnostic characteristic
by pathologists. Hence, new blood vessel formation by
either angiogenesis or vasculogenesis is a critical step
not only for cancer progression as it occurs with all can-
cer types, but is recognised as the event that marks the
frontier between the potential to achieve complete cure
[126] and the stage where removal is feasible but the risk
of dissemination is already acquired and long-term dis-
ease-free status is less likely.
The relevance of angiogenesis as a key event in the
emergence and recognition of early HCC does not
detract the relevance of intense arterial blood supply
both for the development of recurrence after potentially
curative therapy and also for the progression of
advanced cancer. Growth of metastatic nests requires
an extensive net of new arterial vessels to be formed
and not surprisingly, progression from early to
advanced cancer also requires this activity. Manoeuvres
like chemoembolization employed to impair blood sup-
ply and induce ischemic necrosis have been one of the
eﬀective treatments for advanced HCC. Despite being
in place for years, it has just been conﬁrmed recently
that data from randomised controlled trials have dem-
onstrated that chemoembolization (a combination of
arterial obstruction and selective chemotherapy admin-
istration) improves survival of patients that have
reached this evolutionary stage [127]. Hence, acting
against blood supply has become a validated target
and thus the backbone of treatment of HCC diagnosed
at an intermediate stage.The relevance of vascularization in the evolution of
HCC is also reinforced by several studies that have cor-
related the intensity of arterial blood supply or vessel
formation inside the tumour with prognosis [128]. The
same applies for markers of angiogenic activity in
peripheral blood. Increased concentration of VEGF in
serum has been correlated with outcome after surgical
resection [129] or ablation [130]. Interestingly, HCC cell
lines (Fig. 5) derived from human tumours may produce
VEGF by themselves and this demonstrates their pivotal
role in inducing vessel development [131].
All these data have provided the rationale to develop
molecular targeted therapies that could provide an eﬀec-
tive (biology) based treatment of HCC.
5.2. Targeted anti-angiogenic therapy
For years the treatment of HCC has been largely
based on local procedures. Eﬀective options have com-
prised blades, needles and devices aimed at removing
or necrosing tumor cells. However, since cancer is a pro-
cess governed by biologic events, the optimal approach
should target the signals and events that make a malig-
nant cell proliferate, invade, disseminate and survive.
Angiogenesis and vasculogenesis are complex processes
that involve many factors, the best characterized are
ﬁbroblast growth factors (FGFs), vascular endothelial
growth factors (VEGFs) and angiopoietins [132,133].
Recently, other factors such are semaphorin, ephrins
[134], TGF-b/BMP [135] and Notch/Delta have been
added to the list [136,137].
The VEGF growth factors are a family of homodi-
meric glycoproteins that are encoded by 4 VEGF genes
(A–D), and a related growth factor, placental growth
factor (PLGF) encoded by placenta growth factor gene
PlGF [138]. VEGF-A gene produces ﬁve isoforms of
VEGF-A protein, being that of 164 amino acids the iso-
form acting as the strongest mitogen. It is well known
that VEGF-A expression is regulated by hypoxia, glu-
cose concentration, pH and several oncogenes and all
VEGF family members elicit their biological function
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Rs). The binding initiates a cellular response via activa-
tion of the intracellular tyrosine kinase domain of the
receptor. VEGF-R2 (also called KDR) is the key recep-
tor that induces both angiogenesis and vascular perme-
ability [139].
Inhibitors of the VEGF pathway are the best charac-
terized and consequently, the most clinically advanced
agents to inhibit tumour angiogenesis.
At present, these include:
(a) monoclonal antibodies targeting VEGF-A or the
VEGF receptors (mAb)
(b) a variety of small speciﬁc molecule that inhibit
ligand-dependent receptor autophosphorylation of
VEGF-R1 and VEGF-R2 (TKI)
(c) antisense and siRNA targeting VEGF-A or its
receptors
(d) targeting microRNAs can block endothelial cell
migration, proliferation and angiogenesis [140].
VEGF inhibitors induce the arrest of endothelial cell
proliferation, regression of the existing vessels (increas-
ing endothelial cell death), suppress the mobilization
of endothelial progenitor cells from bone marrow (vas-
culogenesis), and are reported to be cytotoxic for some
malignant cells.
Table 2 lists some agents that have undergone inten-
sive investigation. For most, it is assumed that the mech-
anism of action is highly selective, but probably there
are other unknown targets that are aﬀected at the same
time. It is likely that some agents that appear to be eﬀec-
tive are so because of a combination of biological
actions, while agents that would appear similar because
they share the main target, may be useless or deleterious
as a result of the additional molecules that may be
aﬀected. In that sense, clinical studies using VEGFTable 2
Some of the drugs that have shown anti-angiogenic activity and that have been
Agent Class
Bevacizumab (Avastin) mAb
Imatinib (Gleevec) TKI
Dasatinib (Sprycel) TKI
Nilotinib (Tasigna) TKI
Sunitinib (Sutent) TKI
Sorafenib (Nexavar) TKI
AG-013736 (Pﬁzer)
AMG706 (Amgen)
AP23573 (Ariad Pharmaceuticals)
AZD2171 (AstraZeneca)
CCI-779 (Wyeth)
CDP-791 (Imclone Systems)
Everolimus (Novartis)
XL184 (Exelixis)
XL880 (Exelixis)
XL999 (Exelixis)inhibitors have provided a lot of relevant information
but also, a disparity of results. The increasing evidence
of the potential roles of VEGF in other cell types diﬀer-
ent than those implying the vasculature, make the side
eﬀects of anti-VEGF therapies a matter of concern [141].
Since safety of agents does not appear to be homoge-
neous careful adjustment of dosage is needed (a relevant
aspect in patients with liver failure) or consider the
extra-VEGF activity of each. In that sense, the safety
proﬁle and the phase 2 data available with sorafenib
[142] allowed to conduct a phase 3 placebo controlled
randomised clinical trial in patients with advanced
HCC. The results have been unequivocal. Sorafenib
delays tumour progression as evaluated by conventional
radiology criteria and this translates into a highly signif-
icant improvement in survival [143]. Hence, nowadays
sorafenib should be considered the ﬁrst-line systemic
therapy for patients with advanced HCC. Until now,
these patients had no therapeutic option with estab-
lished eﬃcacy and thus, this is a landmark outcome.
However, in addition to the beneﬁts of an eﬀective ther-
apy for the patients with this malignancy, the positive
ﬁndings of sorafenib have major consequences. They
validate antiangiogenics as a useful therapeutic tool
and at the same time, demonstrate that the search and
hope for molecular targeted agents is viable and eﬀec-
tive. Accordingly, clinical trials have to incorporate bul-
lets for additional pathways and/or combine these new
drugs with the one that has been shown to be eﬀective.
Sorafenib is not only an inhibitor of the receptor of vas-
cular endothelial growth factor receptors (VEGFR1-3)
but also of the platelet-derived growth factor receptor-
beta (PDGFR-b), and of the Raf-1 and B-Raf pathway
[144]. Raf kinases are MAPK kinases, key components
of pro-survival pathway [145]. Raf-1 inhibits two pro-
apoptotic kinases both of them implicated in oxidative
stress-induced injury. c-Kit, the receptor for stem cellinvestigated in experimental models and/or in humans.
Target(s)
VEGF-A
ABL1/2, PDGFR a/b, c-Kit
ABL1/2, PDGFR a/b, c-Kit, Src family
ABL1/2, PDGFR a/b, c-Kit
VEGFR1-3,c-Kit,PDGFRa/b,RET,CSF1R, FLT3
VEGFR2,PDGFRb,c-Kit,FLT3,RAF1,BRAF
VEGFR, PDGFR
VEGFR,PDGFR,c-Kit, RET
mTOR, VEGFR
VEGFR1-3, PDGFR
mTOR, VEGFR
VEGFR2
mTOR, VEGFR
MMET,VEGFR,RTK,FLT3,TIE2
c-Met, RTK
VEGFR,PDGFR, EGFR,FLT3, Src
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receptor in normal tissues is to ensure the mobilization
of endothelial progenitor cells to the sites of injury.
Thus, c-Kit inhibition could provide a means of prevent-
ing vasculogenesis in tumours [146]. c-Kit and other ele-
ments are also inhibited at a lower intensity by
sorafenib, and this collateral proﬁle is a key characteris-
tic to be taken into account when thinking of potential
combinations as while eﬃcacy may be increased as
expected, the side eﬀects may also be increased. This is
especially important if it is recalled that in most HCC
there is an underlying liver disease that should not be
further aggravated by the therapy for HCC.
5.3. Summary and future perspectives
There is overwhelming evidence that angiogenesis is
of paramount relevance in the ﬁeld of liver cancer. It
is key in all evolutionary stages of the disease and its
evaluation is important for diagnosis and prognostic
evaluation. At the same time, vessel development and
function has become a therapeutic target for which there
are agents that have shown therapeutic eﬃcacy and
impact in survival.
The advent of sorafenib for advanced HCC is an
excellent example of the potential of research moving
from bench to bedside, not only because of the beneﬁt
for patients, but also importantly since it conﬁrms the
expectations placed in molecular targeted therapies.
Earlier stages of the disease may also beneﬁt from
sorafenib either as an adjuvant or even at preventing
transition from premalignant to malignant stage. Obvi-
ously, combination of agents to increase the eﬃcacy
oﬀered by sorafenib as a single agent is an easy to pro-
pose aim. However, a note of caution has to be raised,
since combination of agents requires a careful preclinical
evaluation of the mix and the conduction of phase 1-2
exploratory trials to deﬁne dosage and safety prior to
going for eﬃcacy, as well as a better knowledge of
molecular pathophysiology.
As in anything in life, expertise and caution permit
advancements, while the opposite may put patients at
risk and misuse valuable resources. Collaborative teams
including cell biologists and physicians should be
encouraged. Only a candid and honest exchange of con-
cepts and data among these multidisciplinary consortia
which in turn will allow the proper design of eﬀective
research plans, based on our current knowledge will
expand and permit a better future for patients with
HCC.
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